Symbol="ACRS"
AssetType="Common Stock"
Name="Aclaris Therapeutics Inc"
Description="Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania."
CIK="1557746"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 400, 101 LINDENWOOD DRIVE, MALVERN, PA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="551844000"
EBITDA="-84357000"
PERatio="None"
PEGRatio="-0.13"
BookValue="2.54"
DividendPerShare="0"
DividendYield="0"
EPS="-1.71"
RevenuePerShareTTM="0.46"
ProfitMargin="0"
OperatingMarginTTM="-3.359"
ReturnOnAssetsTTM="-0.255"
ReturnOnEquityTTM="-0.507"
RevenueTTM="31168000"
GrossProfitTTM="-60021000"
DilutedEPSTTM="-1.71"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.223"
AnalystTargetPrice="29.13"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="43.63"
PriceToBookRatio="4.905"
EVToRevenue="35.36"
EVToEBITDA="-10.0"
Beta="0.604"
num_52WeekHigh="18.96"
num_52WeekLow="5.77"
num_50DayMovingAverage="9.39"
num_200DayMovingAverage="11.47"
SharesOutstanding="70795000"
DividendDate="None"
ExDividendDate="None"
symbol="ACRS"
open="7.57"
high="8.09"
low="7.46"
price="7.50"
volume="1948905.00"
latest_trading_day="2023-08-30"
previous_close="7.59"
change="-0.09"
change_percent="-1.1858%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="49"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="51"
Volume_recent_avg="626297"
Change_recent_avg="-0.01"
Delta_recent_avg="0.46"
Variance_recent_avg="0.23"
Change_ratio_recent_avg="-0.23"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="51"
Aroon_momentum_negative="49"
image_negative_thumbnail_id_1="518"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0087.jpeg"
image_negative_thumbnail_id_2="1124"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0157.jpeg"
image_neutral_thumbnail_id_1="523"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0076.jpeg"
image_neutral_thumbnail_id_2="535"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0064.jpeg"
image_positive_thumbnail_id_1="1011"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0173.jpeg"
image_positive_thumbnail_id_2="600"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0108.jpeg"
image_professor_thumbnail_id_1="1179"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0013.jpeg"
image_professor_thumbnail_id_2="1192"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
